|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR<sup>+</sup>/HER2<sup>-</sup> Breast Cancer.
|
31780379 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibitors in association with aromatase inhibitors have led to a paradigm shift in the management of metastatic positive hormone-receptors breast cancer.
|
31609762 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer.
|
31594766 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to develop a radiolabeled CDK4/6 inhibitor for breast cancer imaging.
|
31481582 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review we provide an up to date overview of the development of anti-cancer agents, particularly the newly developed CDK4/6 inhibitors.<b>Material and methods:</b> A search of PubMed was conducted to identify preclinical data surrounding the development of endocrine therapy and CDK4/6 inhibitors in early and metastatic BC.
|
31671026 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Three Cyclin Dependent Kinase 4/6 (CDK) inhibitors have been approved by the United Stated Food and Drug Administration for front line treatment of advanced hormone receptor positive breast cancer based on improvements in progression free survival against endocrine monotherapy.
|
30513476 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting CDK4/6 pathways and beyond in breast cancer.
|
30359883 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relevance to Patient Care and Clinical Practice: Literature on the safety and efficacy of ribociclib as well as its place in therapy in comparison to other FDA-approved CDK4/6 inhibitors for breast cancer is discussed.
|
30522347 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
After the encouraging results from these clinical trials, CDK4/6 inhibitors have also been investigated in other BC subtypes.
|
30959874 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cdk4-targeting drugs, such as palbociclib, are approved for metastatic ER/PR<sup>+</sup>, Her2<sup>-</sup> breast cancer.
|
30559257 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
|
30099886 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently three different cyclin-dependent kinase 4 and 6 (CDK4/6) dual inhibitors were approved for the treatment of breast cancer (palbociclib, ribociclib, and abemaciclib), all of which offer comparable therapeutic benefits.
|
30401694 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The following review gives a clinical overview of the CDK 4/6 inhibitors in breast cancer therapy and highlight current study data with regard to their antitumor efficacy and toxicities.
|
30520756 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence Ganoderiol F may serve as a potential CDK4/CDK6 inhibitor for breast cancer therapy.
|
31544588 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.
|
30806829 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
As the new standard-of-care in some countries, there is the clinical emergence of patients with breast cancer that is both CDK4/6 inhibitor and endocrine therapy resistant.
|
30389903 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vitro inhibition of CDK4/6 activity has potent antiproliferative properties against luminal breast cancer cell lines, which are enhanced when combined with traditional ET.
|
31709685 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palbociclib, ribociclib, and abemaciclib are FDA-approved CDK4/6 inhibitors used in the treatment of breast cancer.
|
30508677 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest complementary roles of [<sup>18</sup>F]FLT and [<sup>18</sup>F]ISO-1 PET in evaluating tumor-proliferation after combined CDK4/6 inhibitor and endocrine therapy in breast cancer.
|
30692100 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Role of CDK4/6 Inhibitors in Breast Cancer.
|
31101994 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consequently, combination treatment of CDK4/6 inhibitor palbociclib with the eukaryotic initiation factor (eIF) 4A inhibitor, CR-1-31-B, is synergistic in suppressing the growth of these cancer cells <i>in vitro</i> and <i>in vivo</i> Furthermore, ER<sup>+</sup> breast cancer and <i>KRAS</i>-mutant NSCLC cells that acquired resistance to palbociclib after chronic drug exposure are also highly sensitive to this combination treatment strategy.
|
31395685 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 inhibition is now part of the standard armamentarium for patients with estrogen receptor-positive (ER<sup>+</sup>) breast cancer, so that defining mechanisms of resistance is a pressing issue.
|
30840889 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
|
30847853 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the mechanisms by which the CDK4/6 complex is involved in the control of cell growth in triple negative breast cancer (TNBC) are still unclear, some TNBCs might be sensitive to CDK4/6 inhibitors.<b>Areas covered</b>: The authors provide an overview of the treatments that target cell cycle machinery in breast cancer and provide their perspectives for the future.<b>Expert opinion</b>: CDK 4/6 inhibitors are active drugs in HR+ MBC, but some unresolved issues remain.
|
31610139 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the potential mechanism of resistance by establishing a CDK4/6 inhibitor palbociclib-resistant breast cancer cell line (MCF-7pR).
|
30745839 |
2019 |